Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking opioid litigation accruals, thin distribution margins, and segment revenue shifts across McKesson’s 300-page annual report is no small task. Hidden in each 10-K or 8-K are critical clues about cash-flow timing, specialty drug pricing, and how the company’s vast pharmaceutical distribution network manages working capital. That complexity leaves many investors asking, “Where do I even start with McKesson SEC filings explained simply?”
Stock Titan solves that problem. Our platform pairs real-time EDGAR feeds with AI-powered summaries that translate technical disclosures into plain English. Whether you need the latest McKesson quarterly earnings report 10-Q filing, a McKesson 8-K material events explained alert on opioid settlements, or McKesson insider trading Form 4 transactions minutes after they post, we surface the facts and context automatically. You’ll see concise highlights of revenue by distribution segment, inventory turns, and litigation reserve movements—without digging through footnotes.
Use cases span every professional need: monitor McKesson executive stock transactions Form 4 before material announcements, compare gross-margin trends quarter over quarter, or dive into the McKesson proxy statement executive compensation to evaluate incentive alignment. Our coverage includes every form—from a McKesson annual report 10-K simplified to McKesson Form 4 insider transactions real-time—updated the moment they reach EDGAR. Understanding McKesson SEC documents with AI means investors, analysts, and compliance teams gain clear, immediate insights for confident decisions.
McKesson Corporation and the New York Stock Exchange are removing McKesson’s 1.500% Notes due 2025 from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The NYSE filed Form 25, certifying it has reasonable grounds to believe all requirements for delisting are met, and states that the exchange has complied with its rules to strike this debt security from listing. The filing also notes that McKesson has complied with the exchange’s rules and applicable SEC requirements governing the voluntary withdrawal of this class of notes from listing and registration.
McKesson (MCK) insider transaction: The company’s SVP, Controller & CAO reported a Form 4 sale of 329 shares of common stock at $861.63 per share on 11/07/2025 (transaction code S). The filing notes the trade was executed under a Rule 10b5‑1(c) plan adopted on 02/07/2025. Following the sale, the reporting person directly beneficially owned 328 shares.
McKesson Corporation reported stronger Q2 FY26 results. Revenue reached $103.15 billion, up from $93.65 billion a year ago, lifting gross profit to $3.54 billion. Operating income rose to $1.41 billion and net income attributable to McKesson increased to $1.11 billion, or $8.92 diluted EPS (vs. $1.87).
Results reflect lower operating expenses year over year and a $119 million discrete tax benefit, bringing the quarter’s reported tax rate to 16.6%. For the first half, revenue totaled $200.98 billion with net income attributable to McKesson of $1.89 billion and $15.16 diluted EPS. Cash from operations was $1.50 billion.
McKesson expanded its Oncology & Multispecialty segment with two deals: Core Ventures (70% for $2.5 billion) and PRISM Vision (80% for $871 million). It issued $2.0 billion of new notes (4.65% 2030, 4.95% 2032, 5.25% 2035) and ended the quarter with $4.00 billion in cash and $7.76 billion of total debt. The company classified its Norway businesses as held for sale, with net assets of $112 million. Shares outstanding were 123,426,650 as of October 31, 2025.
McKesson Corporation furnished preliminary results for the quarter ended September 30, 2025. The company provided these results in an earnings release attached as Exhibit 99.1, dated November 5, 2025. The information is being furnished to the SEC and is not deemed filed under the Exchange Act.
McKesson (MCK) insider sale reported. The filing shows Chief Executive Officer Tyler Brian S. sold 11,930 shares of McKesson common stock on 08/22/2025 at a reported price of $705.63 per share under a previously adopted 10b5-1 trading plan dated November 8, 2024. After the sale, the report states Mr. Tyler beneficially owned 4,012 shares directly and 215.2588 shares indirectly through the McKesson Corporation 401(k) Retirement Savings Plan. The sale was reported on a Form 4 signed by an attorney-in-fact on 08/25/2025.
Form 144 notice for McKesson Corporation (MCK) shows an intended sale of 11,930 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,418,165.90 and an approximate sale date of 08/22/2025. The shares reported for sale were acquired via restricted stock vesting in three tranches: 9,930 shares on 05/20/2025, 1,333 shares on 05/21/2025 and 667 shares on 05/23/2025; consideration is listed as compensation. The filing discloses prior sales by the same person in the past three months: 19,370 shares on 06/06/2025 for $13,673,864.10, 19,371 shares on 07/11/2025 for $13,716,411.39 and 11,930 shares on 08/15/2025 for $8,085,676.80. The seller is named as Brian S. Tyler with an address shown. The form includes the required attestation that the seller does not possess undisclosed material adverse information.
Tyler Brian S., who is listed as Chief Executive Officer and a director of McKesson Corporation (MCK), reported a sale of 11,930 shares of McKesson common stock on 08/15/2025 at a price of $677.76 per share. After the reported transaction he beneficially owned 15,942 shares directly and 215.2803 shares indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
The filing indicates the sale was made pursuant to a previously adopted plan dated November 8, 2024 and the form was signed by an attorney-in-fact on 08/19/2025. The report includes the reporting persons address in Irving, Texas, and the document is a Section 16 Form 4 disclosure of changes in beneficial ownership.
Form 144 filed for McKesson Corporation (MCK) documents a proposed sale of 11,930 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $8,085,676.80. The 11,930 shares were all acquired as restricted stock vesting on 05/20/2025 (9,930 shares), 05/23/2025 (667 shares), and 05/24/2025 (1,333 shares) as compensation. The notice shows an approximate sale date of 08/15/2025 and names Fidelity Brokerage Services LLC as the broker. The filing also reports insider sales during the past three months by Brian S. Tyler totaling 38,741 shares sold on 06/06/2025 and 07/11/2025 for combined gross proceeds of $27,390,275.49. The form includes the required representation that the seller does not possess undisclosed material adverse information.
FAQ
What is the current stock price of McKesson (MCK)?
What is the market cap of McKesson (MCK)?
